Press room | News

Nov 25, 2015

Teva and Heptares Enter Agreement to Discover and Develop Novel, Small-Molecule CGRP Antagonists for Treatment of Migraine

Oct 2, 2015

Heptares wins Best UK Biotech Dealmaker Award at OBN Annual Awards 2015

Sep 28, 2015

Heptares Awarded $5.5 Million Research & Development Grant from the US National Institute on Drug Abuse (NIDA)

Aug 17, 2015

Heptares’ Pipeline and Novel Approach to GPCR Structure-Guided Drug Discovery and Development Featured in BioCentury

Aug 6, 2015

Heptares and AstraZeneca Enter Agreement to Develop Novel Immuno-Oncology Treatments for a Range of Cancers

Jul 30, 2015

Heptares Initiates Proprietary Therapeutic Antibody Program against a GPCR Target

Jun 25, 2015

Heptares StaR® Technology and its Impact on GPCR Drug R&D featured in New Report Celebrating UK Bioscience from the UK BioIndustry Association

Jun 17, 2015

Positive Outcome of Phase 1a Study with First-Ever Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients with Alzheimer's Disease

May 22, 2015

Heptares Scientist Wins Outstanding Young Chemist Award

Feb 23, 2015

Sosei Acquires Heptares Therapeutics for up to USD 400 million

Jan 23, 2015

Heptares Scientists To Receive The Malcolm Campbell Memorial Prize For 2015 In Recognition Of Their Outstanding Contribution To GPCR Drug Discovery

Jan 22, 2015

Heptares Technology Enables Breakthrough In Drug Discovery Collaboration With AstraZeneca

Jan 8, 2015

Heptares Adds Experts In Drug Discovery And Development To Its Board Of Directors

Back to top

Other News

© 2012-2015 Heptares Therapeutics